Presentation

IRLAB is a Swedish research and development company focused on developing novel treatments for Parkinson's disease. The company's two lead drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), which both have cleared Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and postural dysfunction and falls (PD-Falls). Through the proprietary research platform ISP (Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where growing unmet medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase.